AMBS
vs
S&P 500
AMBS
S&P 500
Over the past 12 months, AMBS has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
AMBS vs S&P 500
Performance Gap
AMBS vs S&P 500
Performance By Year
AMBS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Amarantus Bioscience Holdings Inc
Glance View
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. The company owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. The company is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. The company is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.
